A multicentre, open label and subsequent randomised, double blind, placebo controlled phase III study to assess the safety and efficacy of maintenance and extended therapy with subcutaneously administered onercept of subjects with moderate to severe plaque psoriasis who have either responded or partially responded to an initial 12-week induction treatment with onercept.
Latest Information Update: 03 Aug 2021
At a glance
- Drugs Onercept (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Serono
- 10 Dec 2012 New trial record